Product Description
Dopamine D2 receptor antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11141)
Mechanisms of Action: DR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Belgium | Brazil | Colombia | Dominican Republic | Egypt | France | Italy | Luxembourg | Peru | Portugal | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Institut Jules Bordet
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Breast Cancer
Phase 2: Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-505360-11-00 |
IJB-IRAES-2020 | P2 |
Recruiting |
Oncology Unspecified |
2027-06-30 |
2025-05-02 |
Treatments |
|
NCT01298193 |
GEICAM/2009-02 | P4 |
Completed |
Breast Cancer |
2013-03-01 |
2024-10-16 |
Primary Endpoints|Treatments |